North America
Meta-Analysis Questions FDA Warning on Secondary Cancer Risks With CAR T-Cell Therapies
Researchers analyzed two dozen studies and found similar rates of second primary cancers in patients receiving CAR T-cell and standard therapies.
New Data Shore Up Evidence for Paired Tumor Origin, Molecular Testing in Cancer of Unknown Primary
Premium
Biotheranostics' CancerType ID can predict tumor origins for the majority of CUP patients, with reflex biomarker testing finding those eligible for targeted treatment.
Vir Biotechnology Completes Licensing Deal With Sanofi for Three T-Cell Engager Programs
Vir gained exclusive worldwide rights to HER2-targeted, PSMA-targeted, and EGFR-targeted T-cell engager assets.
In the TRUST-II trial, 85 percent of ROS1 TKI-naïve NSCLC patients and 62 percent of TKI-pretreated patients responded to the next-generation ROS1 inhibitor.
BridgeBio Discontinues Development of Gene Therapy for Congenital Adrenal Hyperplasia
The company said newly released Phase I/II study data for BBP-631 indicated the program did not merit further capital investment.